deltatrials
Completed PHASE3 NCT00065130

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Basal/Bolus Therapy for Patients With Gestational Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Gestational Diabetes
Interventions human insulin insulin NPH insulin aspart
Updated 5 times since 2017 Last updated: Dec 21, 2016 Started: Apr 30, 2000 Primary completion: Dec 31, 2003 Completion: Dec 31, 2003

This PHASE3 trial investigates Diabetes and Gestational Diabetes and is currently completed. Novo Nordisk A/S leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Santa Barbara, United States